Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00135837
Status:
COMPLETED
Last Update Posted:
2006-06-21
First Post:
2005-08-24
Brief Title:
Photodynamic Therapy in Occult-Only Lesions POOL
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An Open-Label Multicenter Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world Blood vessels which start to grow form a lesion in the back of the eye Verteporfin may stabilize the disease by closing the blood vessels This study will assess the efficacy and safety of verteporfin in patients with occult only lesions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None